Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
3
25%
Ph phase_3
2
17%
Ph phase_1
7
58%

Phase Distribution

7

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
7(58.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(5)

Detailed Status

unknown5
Completed5
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (58.3%)
Phase 23 (25.0%)
Phase 32 (16.7%)

Trials by Status

not_yet_recruiting18%
terminated18%
unknown542%
completed542%

Recent Activity

0 active trials
Showing 5 of 12
not_yet_recruitingphase_3

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

NCT06833307
terminatedphase_2

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

NCT05394857
completedphase_1

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

NCT06182384
completedphase_2

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

NCT04840485
completedphase_1

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

NCT03463187
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06833307Phase 3

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Not Yet Recruiting
NCT05394857Phase 2

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Terminated
NCT06182384Phase 1

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Completed
NCT04840485Phase 2

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Completed
NCT03463187Phase 1

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Completed
NCT04924296Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Unknown
NCT04839016Phase 3

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Unknown
NCT03704428Phase 1

Safety, Tolerability and PK of SHR1314 in axSpA

Completed
NCT04527484Phase 1

A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Unknown
NCT04326881Phase 1

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Unknown
NCT03710681Phase 1

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Unknown
NCT02934412Phase 1

A Study of SHR-1314 in Healthy Subjects

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12